{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:56:52Z","timestamp":1781672212520,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007515","name":"Universidad de Valladolid","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007515","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      To systematically review the published literature on clinical trials of gene therapy in patients with choroideremia (\n                      <jats:italic>CHM<\/jats:italic>\n                      gene mutation).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search was conducted in Medline, Cochrane Central Register of Controlled Trials and ClinicalTrials.gov up to April 2026, and was limited to studies published in English or Spanish. Clinical trials evaluating the efficacy of gene therapy in patients with a confirmed molecular diagnosis were included. Methodological quality was assessed using the Revised Cochrane Risk-of-Bias Tool for Randomised Trials and ROBINS-I. A random-effects meta-analysis was performed to compare best-corrected visual acuity (BCVA) in treated versus untreated eyes by standardised mean differences (SMD). Heterogeneity was assessed using the I\u00b2 statistic and the Q test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eight intervention arms from seven clinical trials (377 eyes) assessed the effects of gene therapy on BCVA, showing a small, non-significant improvement (SMD 0.34; 95% CI: -0.52 to 1.19;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.38) with high heterogeneity (I\u00b2=89.6%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Exploratory subgroup analyses by dose suggested differences across dose groups, but these findings should be interpreted cautiously because of the limited number of studies and high heterogeneity. Seven clinical trials (351 eyes) found no significant effect on retinal sensitivity, though lower doses showed more consistent positive trends. Three trials (276 eyes) reported no significant change in foveal thickness overall, with high variability and dose-related differences. No publication bias was detected (Egger\u2019s test:\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.54).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Some individual studies showed significant visual improvements with gene therapy in choroideremia, but the overall pooled effect was modest and not conclusive. High heterogeneity reflects varied study designs and criteria. More rigorous, standardized trials are needed to confirm gene therapy\u2019s efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00417-026-07326-w","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:46:10Z","timestamp":1781671570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gene therapy in patients with choroideremia: a meta-analysis of clinical trials"],"prefix":"10.1007","author":[{"given":"Pablo","family":"Redruello-Guerrero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Ridruejo-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daliana","family":"Gonz\u00e1lez-Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Silva-Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsiana","family":"Stalmashka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Molinero-Sicilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Benites-Narcizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Rivera-Izquierdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Usategui-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Pastor-Idoate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"7326_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/978-3-031-72230-1_9","volume":"1467","author":"A Zhou","year":"2025","unstructured":"Zhou A, Tsang SH, Sharma T, Diaconita V (2025) X-linked choroideremia. Adv Exp Med Biol 1467:43\u201349","journal-title":"Adv Exp Med Biol"},{"key":"7326_CR2","doi-asserted-by":"crossref","unstructured":"Abbass NJ, Yazji I, Allan KC, Kaelber DC, Talcott KE, Singh RP (2025) Trends and Disparities in the Incidence and Prevalence of Inherited Retinal Diseases in the United States. Am J Ophthalmol S0002-9394(25)00375\u20137","DOI":"10.1016\/j.ajo.2025.07.021"},{"key":"7326_CR3","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1136\/bjo-2025-327427","volume":"109","author":"L L\u00e4hteenoja","year":"2025","unstructured":"L\u00e4hteenoja L, Ohtonen P, Falck A, Rahikkala EJ (2025) Characterisation and prevalence of inherited retinal diseases in the Finnish population reveals enrichment of population-specific phenotypes and causative variants. Br J Ophthalmol 109:852\u2013857","journal-title":"Br J Ophthalmol"},{"key":"7326_CR4","doi-asserted-by":"crossref","unstructured":"Abdalla Elsayed MEA, Taylor LJ, Josan AS, Fischer MD, MacLaren RE (2023) Choroideremia: the endpoint endgame. Int J Mol Sci 24:14354, 14354","DOI":"10.3390\/ijms241814354"},{"key":"7326_CR5","volume":"10","author":"A Mitsios","year":"2018","unstructured":"Mitsios A, Dubis AM, Moosajee M (2018) Choroideremia: from genetic and clinical phenotyping to gene therapy and future treatments. Ther Adv Ophthalmol 10:2515841418817490","journal-title":"Ther Adv Ophthalmol"},{"key":"7326_CR6","doi-asserted-by":"crossref","unstructured":"Sobh M, Lagali PS, Ghiasi Mea et al (2023) Safety and efficacy of adeno-associated viral gene therapy in patients with retinal degeneration: a systematic review and meta-analysis. Transl Vis Sci Technol 12:24, 24","DOI":"10.1167\/tvst.12.11.24"},{"key":"7326_CR7","doi-asserted-by":"crossref","unstructured":"Liu Z, Zhang H, Jia Hea et al (2025) The clinical safety landscape for ocular AAV gene therapies: a systematic review and meta-analysis. iScience 28:112265, 112265","DOI":"10.1016\/j.isci.2025.112265"},{"key":"7326_CR8","unstructured":"Ridruejo-Ortega B, Redruello-Guerrero P, Benites Narcizo G, Silva Schultz S, Gonz\u00e1lez Barros D, Estebanez N, Pastor-Idoate S (2024) Efficacy of gene therapy in the treatment of retinal or choroidal dystrophies. In: PROSPERO. https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024578986. Accessed 17 Aug 2025"},{"key":"7326_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page Mea et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"key":"7326_CR10","unstructured":"Sterne JA, Hern\u00e1n MA, McAleenan A, Reeves BC, Higgins JP Chap. 25: Assessing risk of bias in a non-randomized study | Cochrane. Cochrane Handbook for Systematic Reviews of Interventions"},{"key":"7326_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","author":"LA McGuinness","year":"2020","unstructured":"McGuinness LA, Higgins JPT (2020) Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synthesis Methods. https:\/\/doi.org\/10.1002\/jrsm.1411","journal-title":"Res Synthesis Methods"},{"key":"7326_CR12","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","volume":"383","author":"RE MacLaren","year":"2014","unstructured":"MacLaren RE, Groppe M, Barnard AR et al (2014) Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial. Lancet 383:1129\u20131137","journal-title":"Lancet"},{"key":"7326_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaophthalmol.2016.5630","volume":"135","author":"MP Simunovic","year":"2017","unstructured":"Simunovic MP, Xue K, Jolly JK, MacLaren RE (2017) Structural and Functional Recovery Following Limited Iatrogenic Macular Detachment for Retinal Gene Therapy. JAMA Ophthalmol 135:234\u2013241","journal-title":"JAMA Ophthalmol"},{"key":"7326_CR14","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/eye.2017.158","volume":"31","author":"K Xue","year":"2017","unstructured":"Xue K, Groppe M, Salvetti AP, MacLaren RE (2017) Technique of retinal gene therapy: delivery of viral vector into the subretinal space. Eye (Lond) 31:1308\u20131316","journal-title":"Eye (Lond)"},{"key":"7326_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ajo.2018.09.012","volume":"197","author":"BL Lam","year":"2019","unstructured":"Lam BL, Davis JL, Gregori NZ, MacLaren RE, Girach A, Verriotto JD, Rodriguez B, Rosa PR, Zhang X, Feuer WJ (2019) Choroideremia Gene Therapy Phase 2 Clinical Trial: 24-Month Results. Am J Ophthalmol 197:65\u201373","journal-title":"Am J Ophthalmol"},{"key":"7326_CR16","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/IAE.0000000000002360","volume":"40","author":"MD Fischer","year":"2020","unstructured":"Fischer MD, Ochakovski GA, Beier B et al (2020) CHANGES IN RETINAL SENSITIVITY AFTER GENE THERAPY IN CHOROIDEREMIA. Retina 40:160\u2013168","journal-title":"Retina"},{"key":"7326_CR17","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/s41591-018-0185-5","volume":"24","author":"K Xue","year":"2018","unstructured":"Xue K, Jolly JK, Barnard AR et al (2018) Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia. Nat Med 24:1507\u20131512","journal-title":"Nat Med"},{"key":"7326_CR18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ajo.2018.06.011","volume":"193","author":"IS Dimopoulos","year":"2018","unstructured":"Dimopoulos IS, Hoang SC, Radziwon A, Binczyk NM, Seabra MC, MacLaren RE, Somani R, Tennant MTS, MacDonald IM (2018) Two-Year Results After AAV2-Mediated Gene Therapy for Choroideremia: The Alberta Experience. Am J Ophthalmol 193:130\u2013142","journal-title":"Am J Ophthalmol"},{"key":"7326_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ajo.2022.12.022","volume":"248","author":"Y Zhai","year":"2023","unstructured":"Zhai Y, Xu M, Radziwon A, Dimopoulos IS, Crichton P, Mah R, MacLaren RE, Somani R, Tennant MT, MacDonald IM (2023) AAV2-Mediated Gene Therapy for Choroideremia: 5-Year Results and Alternate Anti-sense Oligonucleotide Therapy. Am J Ophthalmol 248:145\u2013156","journal-title":"Am J Ophthalmol"},{"key":"7326_CR20","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.ophtha.2022.06.006","volume":"129","author":"TS Aleman","year":"2022","unstructured":"Aleman TS, Huckfeldt RM, Serrano Lea et al (2022) Adeno-associated virus serotype 2\u2013hCHM subretinal delivery to the macula in choroideremia. Ophthalmology 129:1177\u20131191","journal-title":"Ophthalmology"},{"key":"7326_CR21","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1038\/s41591-023-02520-3","volume":"29","author":"RE MacLaren","year":"2023","unstructured":"MacLaren RE, Fischer MD, Gow JA, Lam BL, Sankila E-M, Girach A, Panda S, Yoon D, Zhao G, Pennesi ME (2023) Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial. Nat Med 29:2464\u20132472","journal-title":"Nat Med"},{"key":"7326_CR22","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1089\/hum.2024.017","volume":"35","author":"RE MacLaren","year":"2024","unstructured":"MacLaren RE, Audo I, Fischer Mea et al (2024) An open-label phase II study assessing the safety of bilateral, sequential administration of retinal gene therapy in participants with choroideremia: the GEMINI study. Hum Gene Ther 35:564\u2013575","journal-title":"Hum Gene Ther"},{"key":"7326_CR23","volume-title":"Gene therapy for choroideremia using an adeno-associated viral vector encoding Rab escort protein 1: the REGENERATE open-label trial","author":"J Cehajic-Kapetanovic","year":"2024","unstructured":"Cehajic-Kapetanovic J, Bellini MP, Taylor LJ, Yusuf IH, Soomro T, da Cruz L, MacLaren RE, REGENERATE Study Group (2024) Gene therapy for choroideremia using an adeno-associated viral vector encoding Rab escort protein 1: the REGENERATE open-label trial. National Institute for Health and Care Research, Southampton (UK)"},{"key":"7326_CR24","doi-asserted-by":"publisher","first-page":"a017293","DOI":"10.1101\/cshperspect.a017293","volume":"5","author":"AR Barnard","year":"2014","unstructured":"Barnard AR, Groppe M, MacLaren RE (2014) Gene therapy for choroideremia using an adeno-associated viral (AAV) vector. Cold Spring Harb Perspect Med 5:a017293","journal-title":"Cold Spring Harb Perspect Med"},{"key":"7326_CR25","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.gim.2021.10.013","volume":"24","author":"AC Britten-Jones","year":"2022","unstructured":"Britten-Jones AC, Jin R, Gocuk SA, Cichello E, Hickey DG, Edwards TL, Ayton LN (2022) The safety and efficacy of gene therapy treatment for monogenic retinal and optic nerve diseases: a systematic review. Genet Med 24:521\u2013534","journal-title":"Genet Med"},{"key":"7326_CR26","first-page":"64","volume":"57","author":"A Abbouda","year":"2021","unstructured":"Abbouda A, Avogaro F, Moosajee M, Vingolo EM (2021) Update on Gene Therapy Clinical Trials for Choroideremia and Potential Experimental Therapies. Med (Kaunas) 57:64","journal-title":"Med (Kaunas)"},{"key":"7326_CR27","doi-asserted-by":"crossref","unstructured":"Bucher K, Rodr\u00edguez-Bocanegra E, Dauletbekov D, Fischer MD (2021) Immune responses to retinal gene therapy using adeno-associated viral vectors - implications for treatment success and safety. Prog Retin Eye Res 83:100915, 100915","DOI":"10.1016\/j.preteyeres.2020.100915"},{"key":"7326_CR28","doi-asserted-by":"crossref","unstructured":"Ong T, Pennesi ME, Birch DG, Lam BL, Tsang SH (2019) Adeno-associated viral gene therapy for inherited retinal disease. Pharm Res 36:34, 34","DOI":"10.1007\/s11095-018-2564-5"},{"key":"7326_CR29","volume":"14","author":"A Girach","year":"2022","unstructured":"Girach A, Audo I, Birch Dea et al (2022) RNA-based therapies in inherited retinal diseases. Ther Adv Ophthalmol 14:25158414221134602","journal-title":"Ther Adv Ophthalmol"},{"key":"7326_CR30","doi-asserted-by":"crossref","unstructured":"Purdy R, John M, Bray Aea et al (2025) Gene therapy-associated uveitis (GTAU): understanding and mitigating the adverse immune response in retinal gene therapy. Prog Retin Eye Res 106:101354, 101354","DOI":"10.1016\/j.preteyeres.2025.101354"},{"key":"7326_CR31","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.omtm.2021.05.011","volume":"22","author":"LC Chandler","year":"2021","unstructured":"Chandler LC, McClements ME, Yusuf IH, de la Martinez-Fernandez C, MacLaren RE, Xue K (2021) Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina. Mol Ther Methods Clin Dev 22:52\u201365","journal-title":"Mol Ther Methods Clin Dev"},{"key":"7326_CR32","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1089\/hum.2022.222","volume":"34","author":"LA Wiley","year":"2023","unstructured":"Wiley LA, Boyce TM, Meyering EE, Ochoa D, Sheehan KM, Stone EM, Mullins RF, Tucker BA, Han IC (2023) The degree of adeno-associated virus-induced retinal inflammation varies based on serotype and route of delivery: intravitreal, subretinal, or suprachoroidal. Hum Gene Ther 34:530\u2013539","journal-title":"Hum Gene Ther"},{"key":"7326_CR33","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.ophtha.2022.06.006","volume":"129","author":"TS Aleman","year":"2022","unstructured":"Aleman TS, Huckfeldt RM, Serrano LW et al (2022) Adeno-Associated Virus Serotype 2-hCHM Subretinal Delivery to the Macula in Choroideremia: Two-Year Interim Results of an Ongoing Phase I\/II Gene Therapy Trial. Ophthalmology 129:1177\u20131191","journal-title":"Ophthalmology"},{"key":"7326_CR34","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/jamaophthalmol.2019.3278","volume":"137","author":"MD Fischer","year":"2019","unstructured":"Fischer MD, Ochakovski GA, Beier B et al (2019) Efficacy and Safety of Retinal Gene Therapy Using Adeno-Associated Virus Vector for Patients With Choroideremia: A Randomized Clinical Trial. JAMA Ophthalmol 137:1247\u20131254","journal-title":"JAMA Ophthalmol"},{"key":"7326_CR35","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1111\/j.1742-1241.2009.02168.x","volume":"63","author":"WL Baker","year":"2009","unstructured":"Baker WL, White CM, Cappelleri JC, Kluger J, Coleman CI, Health Outcomes, Policy, and, Economics, HOPE) Collaborative Group (2009) Understanding heterogeneity in meta-analysis: the role of meta-regression. Int J Clin Pract 63:1426\u20131434","journal-title":"Int J Clin Pract"},{"key":"7326_CR36","doi-asserted-by":"publisher","first-page":"6033","DOI":"10.1167\/iovs.16-20230","volume":"57","author":"MP Simunovic","year":"2016","unstructured":"Simunovic MP, Jolly JK, Xue K, Edwards TL, Groppe M, Downes SM, MacLaren RE (2016) The Spectrum of CHM Gene Mutations in Choroideremia and Their Relationship to Clinical Phenotype. Invest Ophthalmol Vis Sci 57:6033\u20136039","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07326-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07326-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07326-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:46:30Z","timestamp":1781671590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07326-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":36,"alternative-id":["7326"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07326-w","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}